Cargando…
Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546072/ https://www.ncbi.nlm.nih.gov/pubmed/34697341 http://dx.doi.org/10.1038/s41598-021-00539-5 |
| _version_ | 1784590113490075648 |
|---|---|
| author | Shaughnessy, Ciaran A. Zeitlin, Pamela L. Bratcher, Preston E. |
| author_facet | Shaughnessy, Ciaran A. Zeitlin, Pamela L. Bratcher, Preston E. |
| author_sort | Shaughnessy, Ciaran A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8546072 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85460722021-10-27 Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment Shaughnessy, Ciaran A. Zeitlin, Pamela L. Bratcher, Preston E. Sci Rep Author Correction Nature Publishing Group UK 2021-10-25 /pmc/articles/PMC8546072/ /pubmed/34697341 http://dx.doi.org/10.1038/s41598-021-00539-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Shaughnessy, Ciaran A. Zeitlin, Pamela L. Bratcher, Preston E. Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment |
| title | Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment |
| title_full | Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment |
| title_fullStr | Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment |
| title_full_unstemmed | Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment |
| title_short | Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment |
| title_sort | author correction: elexacaftor is a cftr potentiator and acts synergistically with ivacaftor during acute and chronic treatment |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546072/ https://www.ncbi.nlm.nih.gov/pubmed/34697341 http://dx.doi.org/10.1038/s41598-021-00539-5 |
| work_keys_str_mv | AT shaughnessyciarana authorcorrectionelexacaftorisacftrpotentiatorandactssynergisticallywithivacaftorduringacuteandchronictreatment AT zeitlinpamelal authorcorrectionelexacaftorisacftrpotentiatorandactssynergisticallywithivacaftorduringacuteandchronictreatment AT bratcherprestone authorcorrectionelexacaftorisacftrpotentiatorandactssynergisticallywithivacaftorduringacuteandchronictreatment |